Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine.

Abstract

The slow-channel congenital myasthenic syndrome is an autosomal dominant neuromuscular disorder caused by mutations in different subunits of the acetylcholine receptor. Fluoxetine, a common antidepressant and long-lived open-channel blocker of acetylcholine receptor, has been reported to be beneficial in the slow-channel congenital myasthenic syndrome. Here we report a prospective open label study of fluoxetine treatment in some affected members of a Thai family with slow-channel congenital myasthenic syndrome caused by a novel p.Gly153Ala (c.518G > C) mutation in CHRNA1 in the AChR α subunit. These patients showed significant clinical improvement following fluoxetine treatment but their respiratory function responded variably.

• Authors: Charungthai Dejthevaporn, Suppachok Wetchaphanphesat, Teeratorn Pulkes, Sasivimol Rattanasiri, Andrew G Engel, Rawiphan Witoonpanich
• Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (J Clin Neurosci) Vol. 96 Pg. 85-89 (Feb 2022) ISSN: 1532-2653 [Electronic] Scotland
• PMID: 34999496 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Elsevier Ltd. All rights reserved.

Chemical References

• Receptors, Cholinergic
• Fluoxetine

Topics

• Fluoxetine (therapeutic use)
• Humans
• Mutation
• Myasthenic Syndromes, Congenital (drug therapy, genetics)
• Prospective Studies
• Receptors, Cholinergic (genetics)
• Thailand